ViGenCell Inc. (KOSDAQ:308080)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,300.00
-280.00 (-5.02%)
At close: Mar 9, 2026
62.58%
Market Cap 108.65B
Revenue (ttm) 278.95M
Net Income (ttm) -12.56B
Shares Out 20.50M
EPS (ttm) -650.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 296,802
Average Volume 1,420,396
Open 5,300.00
Previous Close 5,580.00
Day's Range 5,090.00 - 5,490.00
52-Week Range 2,635.00 - 17,360.00
Beta 0.72
RSI 34.36
Earnings Date n/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 64
Stock Exchange KOSDAQ
Ticker Symbol 308080
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.